Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Roger D Stanworth & T Hugh Jones. (2008) Testosterone for the aging male; current evidence and recommended practice
. Clinical Interventions in Aging 3:1, pages 25-44.
Read now
Read now
J. M. Kaufman. (2003) The effect of androgen supplementation therapy on the prostate. The Aging Male 6:3, pages 166-174.
Read now
Read now
John B. W. Rietbergen & Fritz H. Schröder. (1998) Screening for Prostate Cancer - More Questions than Answers. Acta Oncologica 37:6, pages 515-532.
Read now
Read now
José L. Teruel, Abelardo Aguilera, Concepción Avila & Joaquín Ortuño. (1996) Effects of Androgen Therapy on Prostatic Markers in Hemodialyzed Patients. Scandinavian Journal of Urology and Nephrology 30:2, pages 129-131.
Read now
Read now
Articles from other publishers (98)
Takahiro Kimura, Shun Sato, Hiroyuki Takahashi & Shin Egawa. (2021) Global Trends of Latent Prostate Cancer in Autopsy Studies. Cancers 13:2, pages 359.
Crossref
Crossref
Jacklin C, Philippou Y, Brewster SF & Bryant RJ. (2021) “More men die with prostate cancer than because of it” - an old adage that still holds true in the 21st century.. Cancer Treatment and Research Communications 26, pages 100225.
Crossref
Crossref
Ersin Erdinç ÇELEBİ, Zülfü SERTKAYA, Musab Ali KUTLUHAN, Selçuk KABA, Metin İshak ÖZTÜRK & Muhammet İhsan KARAMAN. (2020) Prostat Kanserli Yaşlanan Erkekte Palyatif Bakım Kararı. Yeni Üroloji Dergisi.
Crossref
Crossref
Marcio Covas Moschovas, Seetharam Bhat, Onol Fikret, Rogers Travis & Patel Vipul. (2019) Modified simple prostatectomy: an approach to address large volume BPH and associated prostate cancers. Journal of Robotic Surgery 14:4, pages 543-548.
Crossref
Crossref
Subhendu Mandal & Krishnendu Das. (2020) Study on Pattern of Different Prostatic Lesions with Reference to Serum Prostate Specific Antigen (PSA) Level among Autopsy Cases. Journal of Evolution of Medical and Dental Sciences 9:11, pages 863-868.
Crossref
Crossref
Kai Wang, Xinguang Chen, Travis A. Gerke, Victoria Y. Bird, Hans K. Ghayee & Mattia Prosperi. (2018) BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions. Cancer Medicine 7:10, pages 5272-5280.
Crossref
Crossref
Shiying Tang, Han Hao, Dong Fang, Wei Zheng, Peng Ge, Xiaohong Su, Qun He, Xinyu Yang, Qi Shen, Xuesong Li, Wei Yu, Jian Lin & Liqun Zhou. (2018) Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center. International braz j urol 44:2, pages 258-266.
Crossref
Crossref
Szu-Ping Huang, Tzu-Ming Ho, Chih-Wen Yang, Ya-Ju Chang, Jie-Fu Chen, Ning-Sing Shaw, Jia-Cherng Horng, Shih-Lan Hsu, Ming-Yuan Liao, Li-Chen Wu & Ja-an Ho. (2017) Chemopreventive Potential of Ethanolic Extracts of Luobuma Leaves (Apocynum venetum L.) in Androgen Insensitive Prostate Cancer. Nutrients 9:9, pages 948.
Crossref
Crossref
Baowei Fei, Peter T. Nieh, Viraj A. Master, Yun Zhang, Adeboye O. Osunkoya & David M. Schuster. (2016) Molecular imaging and fusion targeted biopsy of the prostate. Clinical and Translational Imaging 5:1, pages 29-43.
Crossref
Crossref
Jaquelyn L. Jahn, Edward L. Giovannucci & Meir J. Stampfer. (2015) The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐era. International Journal of Cancer 137:12, pages 2795-2802.
Crossref
Crossref
Katy J.L. Bell, Chris Del Mar, Gordon Wright, James Dickinson & Paul Glasziou. (2015) Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International Journal of Cancer 137:7, pages 1749-1757.
Crossref
Crossref
Manar Fayiz Atoum, Dena AlKateeb & Sameer Ahmed AlHaj Mahmoud. (2015) The Fok1 Vitamin D Receptor Gene Polymorphism and 25(OH) D Serum Levels and Prostate Cancer among Jordanian Men. Asian Pacific Journal of Cancer Prevention 16:6, pages 2227-2230.
Crossref
Crossref
Ghassan A. Barayan, Fadi Brimo, Louis R. Bégin, James A. Hanley, Zhihui Liu, Wassim Kassouf, Armen G. Aprikian & Simon Tanguay. (2014) Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. BJU International 114:6b, pages E99-E104.
Crossref
Crossref
Thomas R. Jarvis, Bilal Chughtai & Steven A. Kaplan. (2014) Bladder Outlet Obstruction and BPH. Current Bladder Dysfunction Reports 9:4, pages 372-378.
Crossref
Crossref
Gary Onik, Karen Barrie, Matthew Miessau, David Bostwick, David Vaughan, Jeff Brady & William Budd. (2014) Long-Term Results of Optimized Focal Therapy for Prostate Cancer: Average 10-Year Follow-Up in 70 Patients. Journal of Men's Health 11:2, pages 64-74.
Crossref
Crossref
Claus G. Roehrborn. 2012. Campbell-Walsh Urology. Campbell-Walsh Urology
2570
2610.e10
.
Tanner L Bartholow, Uma R Chandran, Michael J Becich & Anil V Parwani. (2011) Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma. Diagnostic Pathology 6:1.
Crossref
Crossref
J. M. Schenk, A. R. Kristal, K. B. Arnold, C. M. Tangen, M. L. Neuhouser, D. W. Lin, E. White & I. M. Thompson. (2011) Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial. American Journal of Epidemiology 173:12, pages 1419-1428.
Crossref
Crossref
Irai S. Oliveira, Jose Pontes-Junior, Daniel K. Abe, Alexandre Crippa, Marcos F. Dall’Oglio, Adriano J. Nesralah, Katia R. M. Leite, Sabrina T. Reis & Miguel Srougi. (2010) Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy. International braz j urol 36:3, pages 292-299.
Crossref
Crossref
David R. Paolone. (2010) Benign Prostatic Hyperplasia. Clinics in Geriatric Medicine 26:2, pages 223-239.
Crossref
Crossref
Laurence KlotzLiying ZhangAdam LamRobert NamAlexandre MamedovAndrew Loblaw. (2010) Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer. Journal of Clinical Oncology 28:1, pages 126-131.
Crossref
Crossref
Stefano Ciatto. (2009) The overdiagnosis nightmare: a time for caution. BMC Women's Health 9:1.
Crossref
Crossref
Riccardo Autorino, Giuseppe Di Lorenzo, Rocco Damiano, Gianluca Giannarini, Marco De Sio, Liang Cheng & Rodolfo Montironi. (2009) Pathology of the prostate in radical cystectomy specimens: A critical review. Surgical Oncology 18:1, pages 73-84.
Crossref
Crossref
Fabrizio Stracci. 2009. Cancer Epidemiology. Cancer Epidemiology
107
136
.
Konstantinos Stamatiou, Andreas Skolarikos, Ioannis Heretis, Vaios Papadimitriou, Alevizos Alevizos, Georgios Ilias, Vasilissa Karanasiou, Anargiros Mariolis & Frank Sofras. (2008) Does educational printed material manage to change compliance with prostate cancer screening?. World Journal of Urology 26:4, pages 365-373.
Crossref
Crossref
Wael Sakr. 2008. Prostate Biopsy. Prostate Biopsy
1
11
.
Yen-Ching Chen, Edward Giovannucci, Peter Kraft, Ross Lazarus & David J. Hunter. (2007) Association between Toll-Like Receptor Gene Cluster (TLR6, TLR1, and TLR10) and Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention 16:10, pages 1982-1989.
Crossref
Crossref
Rocco Damiano, Giuseppe Di Lorenzo, Francesco Cantiello, Marco De Sio, Sisto Perdonà, Massimo D'Armiento & Riccardo Autorino. (2007) Clinicopathologic Features of Prostate Adenocarcinoma Incidentally Discovered at the Time of Radical Cystectomy: An Evidence-Based Analysis. European Urology 52:3, pages 648-657.
Crossref
Crossref
A. B. Miller. (2007) Commentary: Implications of the frequent occurrence of occult carcinoma of the prostate. International Journal of Epidemiology 36:2, pages 282-284.
Crossref
Crossref
Claartje Gosselaar, Monique J. Roobol, Stijn Roemeling, Theo H. van der Kwast & Fritz H. Schröder. (2007) Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics. The Prostate 67:2, pages 154-161.
Crossref
Crossref
Konstantinos Stamatiou, A. Alevizos, E. Agapitos & F. Sofras. (2006) Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: An autopsy study. The Prostate 66:12, pages 1319-1328.
Crossref
Crossref
K Stamatiou, A Alevizos, D Perimeni, F Sofras & E Agapitos. (2005) Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study. Prostate Cancer and Prostatic Diseases 9:1, pages 45-49.
Crossref
Crossref
Fritz H. Schröder, Monique J. Roobol, Theo H. van der Kwast, Ries Kranse & Chris H. Bangma. (2006) Does PSA Velocity Predict Prostate Cancer in Pre-Screened Populations?. European Urology 49:3, pages 460-465.
Crossref
Crossref
Fritz H. Schröder, Claartje Gosselaar, Stijn Roemeling, Renske Postma, Monique J. Roobol & Chris H. Bangma. (2006) PSA and the Detection of Prostate Cancer After 2005. Part I. EAU-EBU Update Series 4:1, pages 2-12.
Crossref
Crossref
Ilario Menchi, Francesca Resi, Paolo Innocenti & Roberto Carpi. 2006. Radiologia geriatrica. Radiologia geriatrica
477
490
.
James B. Bridenstine. (2016) Start Testing Earlier. The American Journal of Cosmetic Surgery 22:4, pages 219-221.
Crossref
Crossref
. (2005) Correct answers to multiple choice questions appearing in the European Urology Update Series 2005. BJU International 96:8, pages 1193-1208.
Crossref
Crossref
Nicolas Barry Delongchamps, Kaili Mao, Hang Theng, Marc Zerbib, Bernard Debré & Michaël Peyromaure. (2005) Outcome of Patients with Fortuitous Prostate Cancer after Radical Cystoprostatectomy for Bladder Cancer. European Urology 48:6, pages 946-950.
Crossref
Crossref
BADRINATH R. KONETY, VICTORIA Y. BIRD, SUNDEEP DEORAH & LAILA DAHMOUSH. (2005) COMPARISON OF THE INCIDENCE OF LATENT PROSTATE CANCER DETECTED AT AUTOPSY BEFORE AND AFTER THE PROSTATE SPECIFIC ANTIGEN ERA. Journal of Urology 174:5, pages 1785-1788.
Crossref
Crossref
MFON S. CYRUS-DAVID, ARMIN WEINBERG, TIMOTHY THOMPSON & DOV KADMON. (2005) THE EFFECT OF STATINS ON SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN A COHORT OF AIRLINE PILOTS: A PRELIMINARY REPORT. Journal of Urology 173:6, pages 1923-1925.
Crossref
Crossref
A. Ruffion, A. Manel, W. Massoud, M. Decaussin, N. Berger, P. Paparel, N. Morel-Journel, J.G. Lopez, D. Champetier, M. Devonec & P. Perrin. (2005) Preservation of prostate during radical cystectomy: Evaluation of prevalence of prostate cancer associated with bladder cancer. Urology 65:4, pages 703-707.
Crossref
Crossref
Claartje Gosselaar, Monique J. Roobol & Fritz H. Schroder. (2005) Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?. BJU International 95:2, pages 231-237.
Crossref
Crossref
Suzanne Stratton & Frederick Ahmann. 2005. Fundamentals of Cancer Prevention. Fundamentals of Cancer Prevention
277
314
.
Sarah Ngan & Jonathan Waxman. 2005. Urological Cancers. Urological Cancers
3
16
.
Maurie Markman. (2004) What is the clinically relevant endpoint for cancer prevention trials?. Current Oncology Reports 6:5, pages 329-330.
Crossref
Crossref
S. Ciatto, A. Vis & P. Finne. (2003) How to improve the specificity and sensitivity of biopsy technique in screening. BJU International 92:s2, pages 79-83.
Crossref
Crossref
S. Ciatto, M. Zappa, A. Villers, A. Paez, S.J. Otto & A. Auvinen. (2003) Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU International 92:s2, pages 97-100.
Crossref
Crossref
F. Boccardo, S. Ciatto & G. Martorana. (2018) Italian National Consensus Conference on Prostate Cancer Screening (Florence, May 17, 2003) - Final Consensus Document. The International Journal of Biological Markers 18:4, pages 238-240.
Crossref
Crossref
J.P. Droz, X. Muracciole, N. Mottet, M. Ould Kaci, J.M. Vannetzel, N. Albin, S. Culine, J.-M. Rodier, J.-L. Misset, S. Mackenzie, E. Cvitkovic & G. Benoit. (2003) Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Annals of Oncology 14:8, pages 1291-1298.
Crossref
Crossref
M Zappa, C Visioli, E Crocetti, C Buonamici, A Baccini, S Taddei & S Ciatto. (2003) Practice of opportunistic PSA screening in the Florence District. European Journal of Cancer Prevention 12:3, pages 201-204.
Crossref
Crossref
M T Tayeb, C Clark, N E Haites, L Sharp, G I Murray & H L McLeod. (2003) CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. British Journal of Cancer 88:6, pages 928-932.
Crossref
Crossref
Stefania Gelmini, Carmela Tricarico, Luisa Petrone, Gianni Forti, Andrea Amorosi, Giovanni L. Dedola, Mario Serio, Mario Pazzagli & Claudio Orlando. (2003) Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate. Clinical Chemistry and Laboratory Medicine 41:3.
Crossref
Crossref
Marco Marcelli, Dolores J. Lamb, Nancy L. Weigel & Glenn R. Cunningham. 2003. Androgens in Health and Disease. Androgens in Health and Disease
157
189
.
Makoto Ohori & Peter T. Scardino. (2002) Localized prostate cancer. Current Problems in Surgery 39:9, pages 843-957.
Crossref
Crossref
RICHARD CHOO, LAURENCE KLOTZ, CYRIL DANJOUX, GERARD C. MORTON, GERRIT DeBOER, EWA SZUMACHER, NEIL FLESHNER, PETER BUNTING & GEORGE HRUBY. (2002) Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical Progression. The Journal of Urology, pages 1664-1669.
Crossref
Crossref
Richard Choo, Laurence Klotz, Cyril Danjoux, Gerard C. Morton, Gerrit DeBoer, Ewa Szumacher, Neil Fleshner, Peter Bunting & George Hruby. (2002) Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical Progression. Journal of Urology 167:4, pages 1664-1669.
Crossref
Crossref
TARA C. POLEK & NANCY L. WEIGEL. (2013) Vitamin D and Prostate Cancer. Journal of Andrology 23:1, pages 9-17.
Crossref
Crossref
Terry R. Brown. 2002. Androgens and Androgen Receptor. Androgens and Androgen Receptor
213
243
.
James M. Kozlowski & Julia A. Sensibar. 2002. Human Cell Culture. Human Cell Culture
305
331
.
J.J. Waxman. 2002. Treatment Options in Urological Cancer. Treatment Options in Urological Cancer
141
159
.
Richard Choo, Gerrit DeBoer, Lawrence Klotz, Cyril Danjoux, Gerard C Morton, Eileen Rakovitch, Neil Fleshner, Peter Bunting, Linda Kapusta & George Hruby. (2001) PSA doubling time of prostate carcinoma managed with watchful observation alone. International Journal of Radiation Oncology*Biology*Physics 50:3, pages 615-620.
Crossref
Crossref
S. Ciatto. (2018) Screening for Prostate Cancer by PSA Determination: A Time for Caution. The International Journal of Biological Markers 15:4, pages 285-287.
Crossref
Crossref
S Ciatto, M Zappa, R Bonardi & G Gervasi. (2000) Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening. European Journal of Cancer 36:11, pages 1347-1350.
Crossref
Crossref
MARCO MARCELLI, T.C. SHAO & GLENN R. CUNNINGHAM. (2000) Endocrinology of Benign and Malignant Prostate Disease in Aging. Journal of Anti-Aging Medicine 3:2, pages 191-200.
Crossref
Crossref
Lukas Bubendorf, Alain Schöpfer, Urs Wagner, Guido Sauter, Holger Moch, Niels Willi, Thomas C. Gasser & Michael J. Mihatsch. (2000) Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology 31:5, pages 578-583.
Crossref
Crossref
Marco Marcelli & Glenn R. Cunningham. (1999) Hormonal Signaling in Prostatic Hyperplasia and Neoplasia*. The Journal of Clinical Endocrinology & Metabolism 84:10, pages 3463-3468.
Crossref
Crossref
Emiel RuijterChristina van de KaaGary MillerDirk RuiterFrans DebruyneJack Schalken. (1999) Molecular Genetics and Epidemiology of Prostate Carcinoma. Endocrine Reviews 20:1, pages 22-45.
Crossref
Crossref
John N. Lewis & William Rising. (2016) Improving Appropriate Selection of Radical Prostatectomy for Prostate Cancer. Evaluation & the Health Professions 21:4, pages 429-441.
Crossref
Crossref
Dunsmuir, Hrouda & Kirby. (2002) Malignant changes in the prostate with ageing. British Journal of Urology 82:S1, pages 47-58.
Crossref
Crossref
M. Zappa, S. Ciatto, R. Bonardi & A. Mazzotta. (1998) Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study. Annals of Oncology 9:12, pages 1297-1300.
Crossref
Crossref
Charles R. Smart. (1997) Prostate cancer facts and fiction. Journal of Surgical Oncology 66:4, pages 223-229.
Crossref
Crossref
Bruce Robinson & Claudia Beghé. (1997) Cancer Screening in the Older Patient. Clinics in Geriatric Medicine 13:1, pages 97-118.
Crossref
Crossref
P. Savage & J. Waxman. (1996) PSA and prostate cancer diagnosis. European Journal of Cancer 32:7, pages 1097-1099.
Crossref
Crossref
A. MandressiB. MangiarottiS. ChisenaD. Antonelli. (2018) Incidental Prostatic Carcinoma. Urologia Journal 63:2, pages 170-187.
Crossref
Crossref
Joseph E. Oesterling. (1996) Benign prostatic hyperplasia: A review of its histogenesis and natural history. The Prostate 29:S6, pages 67-73.
Crossref
Crossref
Ronald M. Benoit, Michael J. Naslund & Paul H. Lange. (1995) Detection of latent prostate cancer from routine screening: Comparison with breast cancer screening. Urology 46:4, pages 533-537.
Crossref
Crossref
Polly Feigl, Brent Blumenstein, Ian Thompson, John Crowley, Michael Wolf, Barnett S. Kramer, Charles A. ColtmanJr.Jr., Otis W. Brawley & Leslie G. Ford. (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clinical Trials 16:3, pages 150-163.
Crossref
Crossref
J. Schubert & S. Kowalik. (1994) The value of prognostic factors in prostatic cancer. International Urology and Nephrology 26:5, pages 541-547.
Crossref
Crossref
J. W. J. VAN DER GULDEN, A. L. M. VERBEEK & J. J. KOLK. (2008) Smoking and drinking habits in relation to prostate cancer. British Journal of Urology 73:4, pages 382-389.
Crossref
Crossref
Gerald W. Chodak, Ronald A. Thisted, Glenn S. Gerber, Jan-Erik Johansson, Jan Adolfsson, George W. Jones, Geoff D. Chisholm, Boaz Moskovitz, Pinhas M. Livne & John Warner. (1994) Results of Conservative Management of Clinically Localized Prostate Cancer. New England Journal of Medicine 330:4, pages 242-248.
Crossref
Crossref
Bradley R. Prestidge, Irving Kaplan, Richard S. Cox & Malcolm A. Bagshaw. (1994) Predictors of survival after a positive post-irradiation prostate biopsy. International Journal of Radiation Oncology*Biology*Physics 28:1, pages 17-22.
Crossref
Crossref
Magda M. Stilmant & Ewa Kuligowska. (1993) Transrectal ultrasound screening for prostatic adenocarcinoma with histopathologic correlation.Factors affecting specificity. Cancer 71:6, pages 2041-2047.
Crossref
Crossref
Anthony L. Zietman, William U. Shipley & Christopher G. Willett. (1993) Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer 71:S3, pages 959-969.
Crossref
Crossref
Arnauld Villers, John E. McNeal, Fuad S. Freiha & Thomas A. Stamey. (1992) Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 70:9, pages 2313-2318.
Crossref
Crossref
David G. Bostwick, William H. Cooner, Louis Denis, George W. Jones, Peter T. Scardino & Gerald P. Murphy. (1992) The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70:S1, pages 291-301.
Crossref
Crossref
R. Launois. 1992. Health Economics Worldwide. Health Economics Worldwide
81
108
.
JOSEPH E. OESTERLING. (2013) The Origin and Development of Benign Prostatic Hyperplasia An Age‐Dependent Process. Journal of Andrology 12:6, pages 348-355.
Crossref
Crossref
Thomas C. Dugan, William U. Shipley, Robert H. Young, Lynn J. Verhey, Alex F. Althausen, Niall M. Heney, Patricia L. McManus & Edward H. Abraham. (1991) Biopsy after External Beam Radiation Therapy for Adenocarcinoma of the Prostate: Correlation with Original Histological Grade and Current Prostate Specific Antigen Levels. Journal of Urology 146:5, pages 1313-1316.
Crossref
Crossref
Thomas J. Kinahan, Martin G. McLoughlin & A. David C. Manson. (1991) Radical Prostatectomy For Localized Prostatic Carcinoma in the Renal Transplant Patient. Journal of Urology 146:1, pages 104-107.
Crossref
Crossref
M. Siadat Pajouh, R. B. Nagle, R. Breathnach, J. S. Finch, Michael K. Brawer & G. Tim Bowden. (1991) Expression of metalloproteinase genes in human prostate cancer. Journal of Cancer Research and Clinical Oncology 117:2, pages 144-150.
Crossref
Crossref
S. Battaglia. 1991. Incidental Carcinoma of the Prostate. Incidental Carcinoma of the Prostate
95
98
.
William J. Catalona. (1990) Prostate cancer. Current Problems in Surgery 27:7, pages 395-461.
Crossref
Crossref
John T. Isaacs. (1990) Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. The Prostate 17:S3, pages 1-7.
Crossref
Crossref
H. Ballentine Carter & Donald S. Coffey. (2006) The prostate: An increasing medical problem. The Prostate 16:1, pages 39-48.
Crossref
Crossref
John T. Isaacs & Donald S. Coffey. (1989) Etiology and disease process of benign prostatic hyperplasia. The Prostate 15:S2, pages 33-50.
Crossref
Crossref
Athanase Billis. (1986) Latent carcinoma and atypical lesions of prostate An autopsy study. Urology 28:4, pages 324-329.
Crossref
Crossref
Hrafn Tulinius. (1984) Late determinants of cancer. Pathology - Research and Practice 179:1, pages 74-80.
Crossref
Crossref
Magnus Piscator. (1981) Role of cadmium in carcinogenesis with special reference to cancer of the prostate. Environmental Health Perspectives 40, pages 107-120.
Crossref
Crossref